Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 20, Issue 12, Pages 1627-1651
Publisher
Informa Healthcare
Online
2010-11-18
DOI
10.1517/13543776.2010.533171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus
- (2010) Lawrence Blonde AMERICAN JOURNAL OF MEDICINE
- Acute or Chronic Upregulation of Mitochondrial Fatty Acid Oxidation Has No Net Effect on Whole-Body Energy Expenditure or Adiposity
- (2010) Kyle L. Hoehn et al. Cell Metabolism
- Insulin Resistance in Nonalcoholic Fatty Liver Disease
- (2010) E. Bugianesi et al. CURRENT PHARMACEUTICAL DESIGN
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
- (2010) R. A. DeFronzo DIABETOLOGIA
- Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6
- (2010) Ken Shimamura et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes
- (2010) Stuart A Morgan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 17β-Hydroxysteroid dehydrogenase inhibitors: a patent review
- (2010) Donald Poirier EXPERT OPINION ON THERAPEUTIC PATENTS
- Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
- (2010) Riccardo C. Bonadonna et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake
- (2010) D. P. Olson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)
- (2009) Serge Léger et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome
- (2009) Bei B. Zhang et al. Cell Metabolism
- GPR40: Good Cop, Bad Cop?
- (2009) T. Alquier et al. DIABETES
- Overexpression of GPR40 in Pancreatic -Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic Mice
- (2009) K. Nagasumi et al. DIABETES
- GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell
- (2009) L. M. Lauffer et al. DIABETES
- The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
- (2009) B. Cariou DIABETES & METABOLISM
- Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
- (2009) Yoshikazu Fujimori et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007 – 2008
- (2009) Jeffrey W Corbett EXPERT OPINION ON THERAPEUTIC PATENTS
- Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
- (2009) William N Washburn EXPERT OPINION ON THERAPEUTIC PATENTS
- Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes
- (2009) Sandip B Bharate et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- GPR119 agonists for the treatment of type 2 diabetes
- (2009) Robert M Jones et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia
- (2009) Kara K. Osbak et al. HUMAN MUTATION
- 11β-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation
- (2009) Mark S. Cooper et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis
- (2009) Hong Lan et al. JOURNAL OF ENDOCRINOLOGY
- Hepatic Fatty Acid Composition Differs between Chronic Hepatitis C Patients with and without Steatosis
- (2009) Bianca M. Arendt et al. JOURNAL OF NUTRITION
- Assessing the potential of glucokinase activators in diabetes therapy
- (2009) Franz M. Matschinsky NATURE REVIEWS DRUG DISCOVERY
- Glucokinase and molecular aspects of liver glycogen metabolism
- (2008) Loranne Agius BIOCHEMICAL JOURNAL
- The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice
- (2008) Ruth Brownlie et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Glucose Sensing in L Cells: A Primary Cell Study
- (2008) Frank Reimann et al. Cell Metabolism
- Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice
- (2008) C. P. Tan et al. DIABETES
- The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat Feeding
- (2008) M. Kebede et al. DIABETES
- Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver
- (2008) A. Kotronen et al. DIABETES
- Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion
- (2008) S. Edfalk et al. DIABETES
- Economic Costs of Diabetes in the U.S. in 2007
- (2008) DIABETES CARE
- Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans
- (2008) N. Stefan et al. DIABETOLOGIA
- Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
- (2008) H. E. Parker et al. DIABETOLOGIA
- A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release
- (2008) Zhi-Liang Chu et al. ENDOCRINOLOGY
- 11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity
- (2008) Katherine A Hughes et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Glucokinase activators as new type 2 diabetes therapeutic agents
- (2008) Ramakanth Sarabu et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119
- (2008) Graeme Semple et al. JOURNAL OF MEDICINAL CHEMISTRY
- Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models
- (2008) Y. Fujimori et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family
- (2008) B. Hagenbuch et al. XENOBIOTICA
- It's Not How Fat You Are, It's What You Do with It That Counts
- (2008) Samuel Virtue et al. PLOS BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now